Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

[1]  Mary G. George,et al.  Effect of Insurance Status on Outcomes of Acute Ischemic Stroke Patients Receiving Intra-Arterial Treatment: Results from the Paul Coverdell National Acute Stroke Program. , 2021, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[2]  B. Zinman,et al.  Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.

[3]  M. Pencina,et al.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial , 2019, JAMA.

[4]  International Association for the Study of Obesity , 2018, The Grants Register 2019.

[5]  J. Segal,et al.  Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients , 2018, Pharmacoepidemiology and drug safety.

[6]  M. Packer.  Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. , 2018, JACC. Heart failure.

[7]  Deepak L. Bhatt,et al.  Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial , 2017, JAMA cardiology.

[8]  9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[9]  T. Stürmer,et al.  No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase‐4 inhibitors vs therapeutic alternatives , 2017, Diabetes, obesity & metabolism.

[10]  Ralph A. DeFronzo,et al.  Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? , 2017, Diabetes Care.

[11]  W. Glasheen,et al.  Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation. , 2017, Journal of diabetes and its complications.

[12]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  F. McAlister,et al.  Defining and validating comorbidities and procedures in ICD-10 health data in ST-elevation myocardial infarction patients , 2016, Medicine.

[14]  Mary G. George,et al.  Accuracy of ICD‐9‐CM Codes by Hospital Characteristics and Stroke Severity: Paul Coverdell National Acute Stroke Program , 2016, Journal of the American Heart Association.

[15]  B. Wells,et al.  Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic , 2016, Journal of diabetes.

[16]  W. Duan,et al.  Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus , 2015, Clinical and experimental pharmacology & physiology.

[17]  L. Pani,et al.  Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. , 2015, European heart journal.

[18]  Laurie Quinn,et al.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. , 2015, Circulation.

[19]  G. Bray,et al.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association , 2015, Diabetes Care.

[20]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[21]  A. Scheen.  Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes , 2015, Expert opinion on drug safety.

[22]  Yu-Sheng Lin,et al.  Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. , 2015, International journal of cardiology.

[23]  G. Fonarow.  Diabetes medications and heart failure: recognizing the risk. , 2014, Circulation.

[24]  S. Schneeweiss,et al.  Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations , 2014, Diabetologia.

[25]  J. Steiner,et al.  Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. , 2014, Journal of the American Pharmacists Association : JAPhA.

[26]  R. Pathak,et al.  Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME‐DM) study , 2014, Pharmacoepidemiology and drug safety.

[27]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the U.S., 2003–2012 , 2014, Diabetes Care.

[28]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[29]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[30]  J. Segal,et al.  Validating the adapted Diabetes Complications Severity Index in claims data. , 2012, The American journal of managed care.

[31]  Jerry H. Gurwitz,et al.  A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.

[32]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[33]  C. Clar,et al.  Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. , 2010, Health technology assessment.

[34]  Charles E. Leonard,et al.  Validation of diagnostic codes for outpatient‐originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data , 2009, Pharmacoepidemiology and drug safety.

[35]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[36]  W. Katon,et al.  Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. , 2008, The American journal of managed care.

[37]  J. Avorn,et al.  Variable selection for propensity score models. , 2006, American journal of epidemiology.

[38]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[39]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[40]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[41]  Lane F Burgette,et al.  Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial on the TWANG Shiny Application for Time-Varying Treatments , 2021 .

[42]  Tzu-hsien Tsai,et al.  A nationwide study , 2020 .

[43]  S. Kuo,et al.  Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. , 2016, Journal of the American Medical Directors Association.

[44]  M. Biddle,et al.  A report from the American Heart Association Council on Cardiovascular and Stroke Nursing. , 2015, The Journal of cardiovascular nursing.

[45]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the , 2014 .

[46]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[47]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .